Search Results - "MALLYA UDUPI, Girish"
-
1
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Published in Cancer research (Chicago, Ill.) (01-02-2013)“…Tumor-infiltrating immune cells can promote chemoresistance and metastatic spread in aggressive tumors. Consequently, the type and quality of immune responses…”
Get full text
Journal Article -
2
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
Published in Cancer research (Chicago, Ill.) (15-07-2017)“…Triple-negative breast cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of biomarkers and…”
Get full text
Journal Article -
3
Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate
Published in Proteomics. Clinical applications (01-07-2019)“…Purpose The tyrosine kinase inhibitor (TKI) sunitinib is a multi‐targeted agent approved across multiple cancer indications. Nevertheless, since approval, data…”
Get full text
Journal Article -
4
-
5
Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
Published in BMC medicine (05-06-2017)“…Cutaneous melanoma is the deadliest skin cancer, with an increasing incidence and mortality rate. Currently, staging of patients with primary melanoma is…”
Get full text
Journal Article -
6
Computer Vision-based Reader for analogue Energy/Water Meters in low-cost embedded System: a Case Study in an Office Building in Scotland
Published in E3S web of conferences (01-01-2020)“…Implementation of cost-effective energy conservation measures (ECMs) is expected to generate up to 18% of carbon emissions reductions in office buildings. In…”
Get full text
Journal Article -
7
Abstract 3010: Proteomic analysis of off-target toxicities following treatment with the tyrosine kinase inhibitor sunitinib
Published in Cancer research (Chicago, Ill.) (15-07-2016)“…Background: Sunitinib is a multi-targeted agent approved for treatment of a number of cancers. However, since approval, data has continually emerged relating…”
Get full text
Journal Article -
8
A Novel Positron Emission Tomography
Published in PloS one (27-01-2017)“…Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors. However, cardiotoxicity is of increasing concern, with a need to…”
Get full text
Journal Article -
9
Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
Published in BMC medicine (05-06-2017)“…Background: Cutaneous melanoma is the deadliest skin cancer, with an increasing incidence and mortality rate. Currently, staging of patients with primary…”
Get full text
Journal Article -
10
Abstract B06: CDK7: A marker of poor prognosis and tractable therapeutic target in triple-negative breast cancer
Published in Molecular cancer research (01-02-2016)“…Triple-negative breast cancer (TNBC) represents a heterogeneous subgroup of breast cancer with substantial genotypic and phenotypic diversity. TNBC patients…”
Get full text
Journal Article